2 citations,
October 2021 in “Exploration of targeted anti-tumor therapy” Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
7 citations,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
5 citations,
August 2012 in “Journal of Dermatology” Tamoxifen may cause female hair loss by increasing androgen receptor expression.
19 citations,
May 2013 in “Annals of Oncology” Aromatase inhibitors cause male pattern hair loss in women.
March 2023 in “Journal of Cosmetic Dermatology” Low-dose oral minoxidil improved hair growth when topical treatments failed.
2 citations,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
68 citations,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
January 2023 in “Mastology” Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.
21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
June 2023 in “Journal of multidisciplinary sciences (Online)” PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
23 citations,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
120 citations,
October 2007 in “Clinical Interventions in Aging” Estrogens help reduce skin aging, and SERMs might offer similar benefits without the risks of hormone therapy.
67 citations,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
56 citations,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
431 citations,
October 2008 in “Current Medicinal Chemistry” Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
37 citations,
September 2018 in “The Journal of Clinical Endocrinology and Metabolism” Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.
25 citations,
June 2019 in “Endocrine Related Cancer” Mutations in certain receptors can cause diseases and offer new treatment options.
90 citations,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.
38 citations,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
January 2014 in “Side effects of drugs annual” Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
January 2015 in “Side effects of drugs annual” The document concludes that sex hormones and related compounds have various effects on health, with both potential benefits and risks.
8 citations,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
May 2024 in “Journal of clinical medicine” Spironolactone is safe for treating female hair loss, but the safety of other drugs is uncertain.
120 citations,
April 2019 in “The Journal of clinical investigation/The journal of clinical investigation” Both estrogens and androgens are important for health in both males and females.
108 citations,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
3 citations,
July 2018 in “Cureus” A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.
28 citations,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
10 citations,
September 2021 in “JAMA Dermatology” Different types of persistent hair loss after chemotherapy respond differently to treatments.
24 citations,
May 2015 in “Molecular and clinical oncology” Honey and bee pollen can help reduce menopausal symptoms in breast cancer patients.